Market research
TBIO Translate Bio Inc
Current ticker: TBIO
NASDAQ USD Healthcare
Latest close
As of 25 Sep 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 3B
- P/E ratio
- 70.62
- Analyst target
- 32.57
- Dividend yield
- 0.0%
- Beta
- 0.97
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US1920032000
- Market cap
- 3B
- P/E ratio
- 70.62
- Analyst target
- 32.57
- Dividend yield
- 0.0%
- Beta
- 0.97
About
About Translate Bio Inc
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts. As of September 13, 2021, Translate Bio, Inc. operates as a subsidiary of Sanofi.
Research context
Translate Bio Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the TBIO discussion.
5 years, 6 months ago
Translate Bio, Inc is currently in a long term uptrend where the price is trading 41.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.2.
Translate Bio, Inc's total revenue rose by 1221.1% to $51M since the same quarter in the previous year.
Its net income has increased by 33.8% to $-21M since the same quarter in the previous year.
Finally, its free cash flow fell by 6.8% to $-23M since the same quarter in the previous year.
Based on the above factors, Translate Bio, Inc gets an overall score of 4/5.